AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03696329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine Tablets 25 mg
Study NCT00818545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER4017 (hydroxypropyltetrahydropyrantriol)
Description: Cream, 10%, each day during 3 months
Study NCT03696329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrabenazine Tablets 25 mg
Study NCT04204070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APAD
Description: APAD
Study NCT00878436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study NCT00878436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study NCT04130737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TORUS Stent Graft System
Description: The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
Study NCT00002805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine
Study NCT00002805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00818545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03406494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early multicomponent physical therapy program
Description: 1. Positioning (upright bed standing; turning, moving on bed).~2. Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~3. Respiratory muscle training (supine abdominal breathing training).~4. Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~5. Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage).
Study NCT00268905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 + carboplatin AUC 5
Description: Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
Study NCT00268905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 + carboplatin AUC 6
Description: After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5.
Study NCT00268905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389+carboplatin AUC 6
Description: In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
Study NCT03375463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT00002805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study NCT00002805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT00002805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00002805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT03375463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered IV
Study NCT03375463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00758784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution 0.06%
Description: bromfenac ophthalmic solution 0.06% bilaterally twice a day
Study NCT01055509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
Study NCT04963829 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration
Description: It is a gel that was used in chronic ulcers healing
Study NCT04963829 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase ointment
Description: Participants who were subjected to a standardized treatment (collagenase ointment)
Study NCT04963829 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gel with 10% peel powder of unripe banana
Description: Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
Study NCT02452164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching
Study NCT02452164 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: (CellScopeOTO)
Study NCT02452164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (CellScopeOTO)
Study NCT00171886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study NCT04025450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide+VRD
Description: Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
Study NCT04025450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VRD
Description: Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
Study NCT03555747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Canine distalization
Description: GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
Study NCT02566928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Description: Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
Study NCT02566928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine wash
Description: Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
Study NCT02566928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene protocol
Description: Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
Study NCT00272597 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: See Detailed Description.
Study NCT02380807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots.
Study NCT02380807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross Tape Therapy
Description: The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
Study NCT03548675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCA treatment
Description: All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
Study NCT03548675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA treatment
Description: All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
Study NCT02170922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS tablet
Study NCT02170922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS solution
Study NCT00456703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative fluid management
Description: fluid restriction
Study NCT03163680 — intervention group
Intervention type: DRUG
Intervention: Omeprazole 40 MG
Description: Omperazole 40 mg twice daily
Study NCT00456703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid restriction
Description: restriction of fluids
Study NCT02822326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T2 Cells
Study NCT01513174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
Study NCT01513174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
Study NCT01513174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
Study NCT05596279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Description: Hybrid IVUS-OCT and control IVUS were performed after stenting
Study NCT05596279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Hybrid IVUS-OCT and control OCT were performed after stenting
Study NCT01139047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole 1% gel
Description: Apply topically once daily on one side of the face for three weeks
Study NCT01139047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: Apply topically twice daily on the opposite side of the face for three weeks
Study NCT02225314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness
Description: Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
Study NCT02225314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InSight
Description: InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
Study NCT02225314 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
Study NCT01848938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone treatment with PFMT
Description: A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
Study NCT03154645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: non-steroidal anti-inflammatory drug
Study NCT03154645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: a diuretic
Study NCT00449592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Oral Zincol 1 Tab TID from day -6/-7 until discharge
Study NCT00449592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo 1 Tab TID from day -6/-7 until discharge
Study NCT01828528 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: An intra-operative liver biopsy was performed in 20 patients
Study NCT01746485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C
Study NCT00002805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00002805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study NCT00002805 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT04456231 — intervention group
Intervention type: DRUG
Intervention: Plenvu
Description: Patients will receive Plenvu for preparation of endoscopy
Study NCT03504943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Intradialytic Exercise
Description: Timing of intradialytic exercise first half of HD
Study NCT03504943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late Intradialytic Exercise
Description: Timing of intradialytic exercise second half of HD
Study NCT02837081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prospective audit strategy of antimicrobial stewardship
Description: applying prospective audit as a different strategy of antimicrobial stewardship
Study NCT02837081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preauthorization strategy of antimicrobial stewardship
Description: applying preauthorization as one strategy of antimicrobial stewardship
Study NCT04744376 — intervention group
Intervention type: OTHER
Intervention: QoR15
Description: Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
Study NCT04744376 — intervention group
Intervention type: OTHER
Intervention: ACS risk calculator
Description: American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
Study NCT04744376 — intervention group
Intervention type: OTHER
Intervention: Clavien - Dindo classification
Description: It is a classification for postoperative complications.
Study NCT03093584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture with indwelling fixed auricular acupuncture needles
Study NCT03093584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Expressive writing is a standard psychological method in treatment of exam anxiety
Study NCT03678870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Education Handout
Description: a single page handout with information about how to use medications for pain after discharge.
Study NCT03177629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment : H. pylori eradication
Description: treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO
Study NCT03177629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment : H. pylori eradication
Description: treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO
Study NCT00729846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
Study NCT00729846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verteporfin photodynamic therapy reduced fluence
Description: Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
Study NCT00729846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verteporfin photodynamic therapy standardfluence
Description: Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
Study NCT01943474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath IV Catheter Device
Description: Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
Study NCT01943474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV Catheter Device
Description: Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
Study NCT02246712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single oral dose of 100 mg racemic tramadol
Description: Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
Study NCT02246712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 100 mg racemic tramadol
Description: Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
Study NCT02246712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6 phenotype
Description: Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato
Study NCT02246712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotype
Description: Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato
Study NCT02246712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CYP3A phenotype
Description: A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance.
Study NCT02246712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP3A phenotype
Description: A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance.
Study NCT02246712 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2B6 genotype
Description: The single nucleotide polymorphism 516G>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).